Epitalon Research & Studies
Part of the full Epitalon guide - a synthetic linear tetrapeptide reference compound, identity-verified with a COA on every vial.
In brief
The Epitalon research record assembled in this entry is small, specific, and almost entirely in-vitro or preclinical, which makes it well suited to a sober reading of what the primary sources actually examined. Five citations anchor the file: the 2003 telomerase study, a 2011 nuclear-penetration and DNA-binding study, a 2020 neurogenesis gene-expression paper, a 2025 IJMS overview, and a 2025 Biogerontology telomere-length study. Together they map onto five declared research areas spanning telomerase regulation, peptide-DNA and peptide-histone binding, transcriptional control of differentiation markers, antioxidant and free-radical readouts, and cellular models of replicative senescence and gerontology. This spoke walks through what each cited source investigated and in which model context, attributing every claim only to the provided literature. The goal is to characterize the evidence base honestly as a set of cultured-cell and invertebrate experiments, not to extrapolate beyond the laboratory systems the authors used.
The detail
A closer look
01
Telomerase and telomere-length studies in cultured human cells
Two citations carry the telomere thread. Khavinson, Bondarev, and Butyugov (2003, Bulletin of Experimental Biology and Medicine, PMID 12937682) reported that the peptide induces telomerase activity and telomere elongation in human somatic cells, specifically inducing hTERT expression and telomerase activity in telomerase-negative human fetal fibroblasts as measured by the TRAP assay. Al-dulaimi, Thomas, Matta, and Roberts (2025, Biogerontology, PMID 40908429) extended the question across human cell lines, reporting that Epitalon increases telomere length either through telomerase upregulation or through ALT activity depending on the line. Read together, these define the in-vitro replicative-senescence and gerontology research area: the systems are cultured human cell lines, the assays are enzymatic and length-based, and the reported outcomes concern telomere maintenance machinery rather than any whole-organism endpoint.
02
Nuclear penetration, DNA binding, and the epigenetic hypothesis
The mechanistic backbone of the research area comes from Fedoreyeva, Kireev, Khavinson, and Vanyushin (2011, Biochemistry Moscow, PMID 22117547), who studied penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and characterized in-vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. This is the source for the claim that AEDG reaches the nucleus and binds nucleic acids sequence-specifically. Khavinson, Diomede, Mironova, and colleagues (2020, Molecules, PMID 32019204) built on this with a study titled around a possible epigenetic mechanism, examining AEDG stimulation of gene expression and protein synthesis during neurogenesis in human mesenchymal stem cell culture. Together these two papers supply the peptide-DNA and peptide-histone binding research area and the transcriptional-regulation-of-differentiation-markers area, both framed explicitly as epigenetic models.
03
Differentiation markers, antioxidant readouts, and review context
The neurogenesis work (Khavinson et al., 2020) reported increased mRNA and protein for Nestin, GAP43, beta-Tubulin III, and Doublecortin in cultured human mesenchymal stem cells, populating the transcriptional and translational regulation research area. The entry also lists antioxidant and free-radical readouts in cell and invertebrate model systems and modulation of IL-2 mRNA among the studied effects, situating AEDG in redox and immune-transcript model work without attaching whole-organism claims. The fifth citation, Araj, Brzezik, Madra-Gackowska, and Szeleszczuk (2025, International Journal of Molecular Sciences, PMID 40141333), is an overview of Epitalon as a highly bioactive pineal tetrapeptide and provides the origin and class context, attributing development to the V.Kh. Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Epitalon is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.